Labomar S.p.A. researches, develops, manufactures, and sells food supplements, medical devices, cosmetics, and pharmaceutical products in Italy, France, Poland, Spain, North America, and internationally. It offers food supplements for various therapeutic areas, including immune systems, gastroenterology, cough and cold, neurology, oncology, eyesight wellness, sport, dermatology, inside beauty, cardiology, orthopedics, pediatrics, detoxing, and metabolic syndrome; and vitamins, minerals, and antioxidants. The company also provides medical devices for the use in gynaecology, cough and cold, gastroenterology, wound healing, metabolic syndrome, proctology, detoxing, and oral wound care therapeutic areas; and foods for special medical purposes, such as gastroenterology, endocrinology, and dysphagia. In addition, it offers cosmetics for inside beauty, skin cleanser, skincare, haircare, oral wound care, sun care, dermatology, acne rosacea, acne, atopic dertmatitis, and bruises therapeutic areas; and probiotic food supplements. Further, the company provides contract development and manufacturing services. Labomar S.p.A. offers its products in the form of tablets, capsules, liquids, powders, and semi solids. It has a commercial agreement with Bayer for the development and production of the references in various pharmaceutical flavors and forms. The company was founded in 1998 and is headquartered in Istrana, Italy.

Labomar S.p.A.

Labomar develops and manufactures nutraceuticals and health supplements, focusing on innovation and safety in its products. The company is self-described as a Certified B Corporation, reflecting its commitment to social and environmental performance.

LBM

COM:LABOMAR

Labomar

Last Close

10.00

23/08 12:12

Market Cap

183.92M

Beta: -

Volume Today

1.75K

Avg: -

Financials Not Available